Newstral
Article
jdsupra.com on 2017-09-06 20:29
Amgen v. Apotex: Federal Circuit Oral Argument Set
Related news
- Amgen v. Hospira: Federal Circuit Oral Argument Heldjdsupra.com
- Federal Circuit Issues Mandate in Amgen v. Apotexjdsupra.com
- Federal Circuit Affirms District Court in Amgen v. Apotexjdsupra.com
- Act II: Oral Argument in Amgen v. Sandoz is heard at the Court of Appeals for the Federal Circuitjdsupra.com
- Federal Circuit Oral Arguments in Amgen v. Sandozjdsupra.com
- Federal Circuit Provides Guidance on Statements in Patent Dance Letters and Sunovion in Amgen v Apotexjdsupra.com
- Amgen v. Sandoz -- Federal Circuit Oral Argumentjdsupra.com
- Amgen v. Apotex, Petition for Certiorarijdsupra.com
- Federal Circuit Decides Amgen v. Apotex, Holds that 180-Day Notice of Commercial Marketing is Always Mandatory in Biosimilar Litigationjdsupra.com
- Briefing Complete in Appeal in Amgen v. Apotexjdsupra.com
- Breaking News: CAFC Affirms in Amgen v. Apotexjdsupra.com
- Supreme Court Denies Cert. in Apotex v. Amgenjdsupra.com
- Amgen v. Apotex: Analysis of the Fed. Cir. Opinionjdsupra.com
- Solicitor General Supports Cert in Amgen v. Sandoz, Supreme Court Denies Cert in Amgen v. Apotexjdsupra.com
- Amgen and Hospira Square Off Over BPCIA Private Right of Action After Amgen v. Apotex Rulingjdsupra.com
- Amgen v. Apotex: Amgen Appeals Non-Infringement Judgment in Filgrastim/Pegfilgrastim Disputejdsupra.com
- Amgen v. Hospira: Amgen Files Appeal Brief at Federal Circuitjdsupra.com
- Biosimilars Council Files Amicus Brief in support of Apotex’s Petition for Certiorari in Amgen v. Apotexjdsupra.com
- UPDATE: Mylan Files Amicus Brief in Support of Apotex’s Petition in Amgen v. Apotexjdsupra.com
- The Ripple Effect of the Federal Circuit’s Decision in Amgen v. Apotex on Biosimilar Litigationjdsupra.com